Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hülsmeier, Andreas J ^a   Tobler, Micha ^b   Burda, Patricie ^b   Hennet, Thierry ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

BLOOD; COMPLICATION; CONGENITAL DISORDER OF GLYCOSYLATION; FEMALE; GLYCOSYLATION; HUMAN; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER;

BIOMARKERS; CONGENITAL DISORDERS OF GLYCOSYLATION; FEMALE; GLYCOSYLATION; HAPTOGLOBINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84991233696     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33927     Document Type: Article

References (43)

1. Neuman, M. G. et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol 97, 492-510, doi: 10.1016/j.yexmp.2014.09.005 (2014).
2. Altamirano, J. & Bataller, R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol 8, 491-501, doi: 10.1038/nrgastro.2011.134 (2011).
3. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523, doi: 10.1126/science.1204265 (2011).
4. Loomba, R. et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology 149, 1784-1793, doi: 10.1053/j.gastro.2015.08.011 (2015).
5. Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47, 181-190, doi: 10.1016/j.dld.2014.09.020 (2015).
6. Fitzpatrick, E. & Dhawan, A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 20, 10851-10863, doi: 10.3748/wjg.v20.i31.10851 (2014).
7. Spengler, E. K. & Loomba, R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 90, 1233-1246, doi: 10.1016/j.mayocp.2015.06.013 (2015).
8. Ohtsuka, T., Tsutsumi, M., Fukumura, A., Tsuchishima, M. & Takase, S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res 29, 236S-239S (2005).
9. Callewaert, N. et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10, 429-434 (2004).
10. Liu, X. E. et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46, 1426-1435, doi: 10.1002/hep.21855 (2007).
11. Blomme, B. et al. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis 44, 315-322, doi: 10.1016/j.dld.2011.10.015 (2012).
12. Chen, C. et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 8, 463-470, doi: 10.1021/pr800656e (2009).
13. Jaeken, J., Hennet, T., Matthijs, G. & Freeze, H. H. CDG nomenclature: time for a change! Biochimica et biophysica acta 1792, 825-826, doi: 10.1016/j.bbadis.2009.08.005 (2009).
14. Arndt, T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clinical chemistry 47, 13-27 (2001).
15. Bean, P. & Peter, J. B. Allelic D variants of transferrin in evaluation of alcohol abuse: differential diagnosis by isoelectric focusingimmunoblotting-laser densitometry. Clinical chemistry 40, 2078-2083 (1994).
16. Helander, A., Bergstrom, J. & Freeze, H. H. Testing for congenital disorders of glycosylation by HPLC measurement of serum transferrin glycoforms. Clinical chemistry 50, 954-958, doi: 10.1373/clinchem.2003.029629 (2004).
17. Lacey, J. M., Bergen, H. R., Magera, M. J., Naylor, S. & O'Brien, J. F. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clinical chemistry 47, 513-518 (2001).
18. Hülsmeier, A. J., Paesold-Burda, P. & Hennet, T. N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6, 2132-2138, doi: 10.1074/mcp.M700361-MCP200 (2007).
19. Plomp, R., Bondt, A., de Haan, N., Rombouts, Y. & Wuhrer, M. Recent advances in clinical glycoproteomics of immunoglobulins. Mol Cell Proteomics, doi: 10.1074/mcp.O116.058503 (2016).
20. Anthony, R. M. & Ravetch, J. V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. Journal of clinical immunology 30 Suppl 1, S9-14, doi: 10.1007/s10875-010-9405-6 (2010).
21. Maratha, A. et al. Classical galactosaemia: novel insights in IgG N-glycosylation and N-glycan biosynthesis. Eur J Hum Genet, doi: 10.1038/ejhg.2015.254 (2016).
22. Saldova, R. et al. N-Glycosylation of Serum IgG and Total Glycoproteins in MAN1B1 Deficiency. J Proteome Res 14, 4402-4412, doi: 10.1021/acs.jproteome.5b00709 (2015).
23. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25, 21-50, doi: 10.1146/annurev.immunol.25.022106.141702 (2007).
24. van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The Emerging Importance of IgG Fab Glycosylation in Immunity. J Immunol 196, 1435-1441, doi: 10.4049/jimmunol.1502136 (2016).
25. Suzuki, H. et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118, 629-639, doi: 10.1172/JCI33189 (2008).
26. McCarthy, C. et al. The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res 13, 3131-3143, doi: 10.1021/pr500146y (2014).
27. Dempsey, E. & Rudd, P. M. Acute phase glycoproteins: bystanders or participants in carcinogenesis? Ann N Y Acad Sci 1253, 122-132, doi: 10.1111/j.1749-6632.2011.06420.x (2012).
28. Stibler, H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clinical chemistry 37, 2029-2037 (1991).
29. Peter, J. et al. Identification of carbohydrate deficient transferrin forms by MALDI-TOF mass spectrometry and lectin ELISABiochim Biophys Acta 1998 Aug 24;1381(3):356. Biochimica et biophysica acta 1380, 93-101 (1998).
30. Grünewald, S., Schollen, E., Van Schaftingen, E., Jaeken, J. & Matthijs, G. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am J Hum Genet 68, 347-354, doi: 10.1086/318199 (2001).
31. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321, doi: 10.1002/hep.20701 (2005).
32. Hong, Q. et al. A Method for Comprehensive Glycosite-Mapping and Direct Quantitation of Serum Glycoproteins. J Proteome Res 14, 5179-5192, doi: 10.1021/acs.jproteome.5b00756 (2015).
33. Satomi, Y., Shimonishi, Y. & Takao, T. N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin. FEBS letters 576, 51-56, doi: 10.1016/j.febslet.2004.08.061 (2004).
34. Morell, A. G., Gregoriadis, G., Scheinberg, I. H., Hickman, J. & Ashwell, G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246, 1461-1467 (1971).
35. Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17, 104-118, doi: 10.1093/glycob/cwl057 (2007).
36. Zheng, K., Bantog, C. & Bayer, R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 3, 568-576, doi: 10.4161/mabs.3.6.17922 (2011).
37. Dupre, T. et al. Defect in N-glycosylation of proteins is tissue-dependent in congenital disorders of glycosylation Ia. Glycobiology 10, 1277-1281 (2000).
38. Pompach, P. et al. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics 12, 1281-1293, doi: 10.1074/mcp.M112.023259 (2013).
39. Zhu, J. et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res 13, 2986-2997, doi: 10.1021/pr500128t (2014).
40. Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M. & Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128-133, doi: 10.1002/hep.510270121 (1998).
41. Kamada, Y. et al. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One 8, e66328, doi: 10.1371/journal.pone.0066328 (2013).
42. Kamada, Y. et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology 62, 1433-1443, doi: 10.1002/hep.28002 (2015).
43. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968, doi: 10.1093/bioinformatics/btq054 (2010).